Document:

EX-10.D.2:

 

EXHIBIT 10(d.2)

EMPLOYMENT AGREEMENT

     This Agreement (“Agreement”) made this 20th day of March, 1997, between DUSA Pharmaceuticals,
inc., a New Jersey corporation (the “Corporation”) and D. Geoffrey Shulman, MD, FRCPC (“Dr.
Shulman”).

     WHEREAS, the parties entered into an Employment Agreement dated October 1, 1991 whereby Dr.
Shulman was appointed as Chairman, President, and Chief Executive Officer and Chief Operating
Officer of the Corporation.

     WHEREAS, such Employment Agreement was amended on April 14, 1994.

     WHEREAS, the parties now wish to renew such Employment Agreement.

     NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

     1. Employment: The Corporation hereby employs Dr. Shulman and he hereby accepts such
employment as the Chairman, President, Chief Executive Officer and Chief Operating Officer of the
Corporation. Dr. Shulman agrees to devote his best efforts and spend as much time and attention as
is necessary to manage the affairs of the Corporation.

     2. Medical Practice: The Corporation agrees that Dr. Shulman shall be entitled to conduct his
medical practice during one (1) day each week, Monday through Friday, at his discretion.

     3. Board of Directors: So long as this Agreement remains in effect, Dr. Shulman will be a
member of the Board of Directors (the “Board”) and an officer of the Corporation and shall possess
the powers set forth in the Corporation’s Certificate of Incorporation and By-Laws.

     4. Term of Office and Employment: The term of this Agreement shall be effective as of October
1, 1996, nunc pro tunc, and continue for a period of five (5) years until
September 30, 2001 and shall automatically renew for successive one (1) year periods thereafter,
unless earlier terminated in accordance with the provisions of this Agreement.

     5. Duties and Responsibilities: Notwithstanding any language contained herein to the
contrary, Dr. Shulman shall be responsible (by way of example and not by way of limitation) for:

	 	a)	 	the general direction and operations of the business of the Corporation;
	 
	 	b)	 	the management of the financial affairs of the Corporation;
	 
	 	c)	 	the custody of corporate funds and securities;
	 
	 	d)	 	the hiring, training, direction, discipline and compensation of the employees
and other officers of the Corporation, subject to approval by the Board of the salaries
and benefits, including stock options which may be offered to other officers and
executives; and

     6. Remuneration: The Corporation will pay to Dr. Shulman a base salary equal to U.S. $250,000
per annum. This base salary shall be reviewed by the Board from time to time,

 

 

not less than on an annual basis. Any salary increases from time to time, shall be determined
by, and at the discretion of the Board. Following the end of each fiscal year, the Board may award
a cash bonus to Dr. Shulman in an amount up to 50% of Dr. Shulman’s current base salary for such
year, as determined by the Board in its sole discretion. The Board may award annual cash bonuses
above 50% of his current base salary for outstanding performance.

     All salary and other payments and allowances outlined in this Agreement shall be subject to
such withholding taxes and deductions at source as may be required by law. All monetary references
made herein shall refer to U.S. dollars.

     7. Benefits: Dr. Shulman will be entitled to participate in the medical, disability, life and
other insurance benefit plans which will be made available to the officers and employees of the
Corporation from time to time, subject to applicable eligibility rules thereof. Further, the
Corporation shall maintain for Dr. Shulman key man life insurance with the Corporation named as
beneficiary throughout the term of this Agreement, assuming reasonable quotations are available.

     8. Stock Purchase and Bonus Plans: Dr. Shulman will be entitled to participate in the stock
purchase and bonus plans that the Corporation shall from time to time make available to its
officers and employees, subject to applicable eligibility rules thereof.

     9. Vacation: Each calendar year, Dr. Shulman shall be entitled to four (4) weeks of vacation
per annum to be taken at a time or times acceptable to the Corporation, having regard to its
operations. Dr. Shulman shall be entitled to carry over any unused vacation from one (1) calendar
year into the following calendar year, so long as such vacation policy is consistent for all
employees.

     10. Expenses: The Corporation agrees that it will reimburse Dr. Shulman for all reasonable
and authorized traveling and other out-of-pocket expenses actually and properly incurred by Dr.
Shuman in connection with his employment duties upon provision of appropriate statements, vouchers,
bills and invoices as and when required by the Corporation. Dr. Shulman shall be paid $4,000.00
per year as an automobile allowance in recognition of his regular business acquired by the
Corporation.

     11. Confidential Information:

	 	a)	 	Dr. Shulman shall not (either during the continuance of his employment with the
Corporation or for two (2) years thereafter): (i) disclose to any person, other than it
the necessary course of business, any private, confidential or secret information that
belongs to the Corporation; or (ii) engage in any business substantially similar to
that of the Corporation’s in any area in which the Corporation conducted business
during the term of this Agreement. Without limiting the generality of the foregoing,
Dr. Shulman will not disclose, among other things, any information about:

	 	i)	 	newly developed products of the Corporation;
	 
	 	ii)	 	manufacturing processes and technologies;
	 
	 	iii)	 	research in progress and any unpublished formula, findings,
manuals, or know-how;
	 
	 	iv)	 	regulatory filings;

-2-

 

	 	v)	 	identity of and relationships to licensees of the Corporation;
	 
	 	vi)	 	finances, financial information and financial management
systems of the Corporation and any other research, information or documents
which he knows or reasonably ought to know that the Corporation regards as
proprietary or confidential to any person other than for the Corporation’s
purposes and shall not use for his purposes or for any purposes of the
Corporation any such information or secrets which he may acquire in relation to
the business of the Corporation.

	 	b)	 	Notwithstanding any of the foregoing in this section, information, whether
confidential or proprietary or not, shall be exempt from the above confidentiality
provisions if said information:

	 	i)	 	was known to Dr. Shulman prior to his employment with the
Corporation;
	 
	 	ii)	 	was in the public domain on the date of employment;
	 
	 	iii)	 	becomes public at any time through no fault of Dr. Shulman; or
	 
	 	iv)	 	is or in the future becomes readily available from third
parties who have no confidentiality obligations to the Corporation.

     12. Termination of Employment:

	 	a)	 	Termination for Cause: The Corporation may terminate this Agreement at any
time for cause without notice Cause shall include, but not be limited to, Dr. Shulman’s
inability to perform the duties of his job for any cause for a period in excess of six
(6) consecutive months. In the event of a termination for cause, Dr. Shulman shall be
paid his base salary, pro rated to the date of termination.
	 
	 	b)	 	Termination without Cause: If Dr. Shulman’s employment is terminated without
cause, the Corporation shall:

	 	i)	 	pay Dr. Shulman a severance allowance equivalent to one (1)
year’s then current base salary, payable as a lump sum, within sixty (60) days
following the date of such termination;
	 
	 	ii)	 	pay to Dr. Shulman within two (2) weeks of the date of
termination all outstanding vacation pay and any earned but unpaid salary or
bonuses to the date of such termination and reimburse Dr. Shulman for any
business expense incurred by him up to and including the date of such
termination following provision by Dr. Shulman of all applicable and necessary
receipts;
	 
	 	iii)	 	allow Dr. Shulman the right to exercise for a period of one (1)
year from the date of termination all stock options granted to him pursuant to
the terms of this Agreement or otherwise, or any stock option plan in effect
prior to his termination as to all or any part of the shares covered by such
options, including shares with respect to which such options would not
otherwise be exercisable, subject to restrictions under U.S. or Canadian law,
as applicable;

-3-

 

	 	 	 	The payments referred to in (i) and (ii) above shall not be subject to set-off or
deduction as a result of Dr. Shulman obtaining alternate employment following such
termination or otherwise mitigating any damages arising from such termination.
	 
	 	c)	 	Fair and Reasonable: The parties confirm that the payments described above are
fair and reasonable and the parties agree that upon any termination without cause, Dr.
Shulman shall have no action, cause of action, claim or demand, either statutory or at
common law against the Corporation or any other person as a consequence of such
termination without cause.
	 
	 	d)	 	Termination upon Death: Dr. Shulman’s employment with the Corporation will
cease without further notice or further compensation if Dr. Shulman dies. Upon his
death, his heirs or beneficiaries will be entitled to any Corporation paid death
benefit in force at the time of such death. Likewise, Dr. Shulman’s heirs will be
entitled to exercise any vested but unexercised stock options that were held by him at
the time of his death. His heirs must exercise such options within one (1) year from
the date of death.
	 
	 	e)	 	Termination Upon Change in Control: If prior to the expiration of this
Agreement there shall occur a “change in control” as defined herein, Dr. Shulman shall
receive, within five (5) days after such termination from the Corporation or its
successor, a lump sum payment equal to three (3) times his base salary during the last
fiscal year in which Dr. Shulman is associated with the Corporation. For the purposes
hereof, “change in control” shall mean a change in control of a nature that would be
required to be reported in response to Item 5 of Schedule 14D promulgated pursuant to
Section 14 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), whether
or not the Corporation is then subject to such reporting requirements; provided that,
without limitations, such a change in control shall be deemed to have occurred if (i)
any person other than a trustee or other fiduciary holding securities under an employee
benefit plan of the Corporation is or becomes the beneficial owner, directly or
indirectly, of securities of the Corporation representing twenty percent (20%) or more
of the combined voting power of the Corporation’s then outstanding securities and
thereafter the Board adopts a resolution to the effect that, for the purposes of this
Agreement, a change in control of the Corporation has occurred; such ownership shall be
as defined pursuant to Rule 13d-3 of the 1934 Act and includes mergers or acquisitions
whereby an outside party has in excess of twenty percent (20%) of the combined voting
power; (ii) when the Corporation merges or consolidates with any other person or,
entity other than a subsidiary and, upon consummation of such transaction, holders of
the Corporation’s common stock immediately prior to such transaction own less than
fifty percent (50%) of the equity securities of the surviving or consolidated entity;
or (iii) a substantial portion of the assets of the Corporation are sold or transferred
to another person or entity.
	 
	 	f)	 	Resignation: Dr. Shulman will provide the Corporation with three (3) months’
notice, in writing, of his resignation from the Corporation.

     13. Indemnification: The Corporation will, to the extent permitted by the laws of the State
of New Jersey, U.S.A., indemnify Dr. Shulman against any actual or threatened action, suit or
proceeding, whether civil, criminal, administrative or investigative, that arises as a consequence
of his duties as an officer of the Corporation. Such indemnification will include such expenses as
attorneys fees, judgments, fines and amounts awarded or agreed to in settlement, provided that Dr.
Shulman acted legally and in good faith, or reasonably believed that

-4-

 

his actions were legal and performed in good faith. The termination of any action, suit or
proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendre shall not,
of itself, create a presumption that his actions were illegal or not performed in good faith.

     14. Provisions Operating Following Termination: Notwithstanding any termination of Dr.
Shulman’s employment with or without cause, any provision of this Agreement necessary to give it
efficacy shall continue in full force and effect following such termination.

     15. Notices: Any notice to be given in connection with this Agreement shall be given in
writing and may be given by personal delivery, by certified mail, postage prepaid, or by facsimile
transmission, so long as receipt of such transmission is available, addressed to the recipient as
follows:

	 	 	 
	To:

	 	D. Geoffrey Shulman, MD, FRCPC
	 

	 	256 Russell Hill Road
	 

	 	Toronto, Ontario M4V 2T2
	 

	 	CANADA
	 
	 	 
	To:

	 	Anthony Schincariol,
	 

	 	Vice President of Corporate Development
	 

	 	181 University Avenue
	 

	 	Suite 1208
	 

	 	Toronto, Ontario M5H-3M7
	 

	 	CANADA

or to such other address or individual as may be designated by notice by either party to the other.
Any notice given by personal delivery shall be deemed to have been given on the day of actual
delivery and, if made or given by certified mail, on the third day, other than a Saturday, Sunday,
or a statutory holiday in Toronto, Ontario, CANADA following the deposit thereof with the U.S.
Postal Service.

     16. Governing Law: This Agreement shall be governed by and construed in accordance with the
laws of the State of New Jersey, U.S.A.

     17. Benefit of Agreement: This Agreement shall enure to the benefit of and be binding upon
the heirs, executives, administrators and legal personal representatives of Dr. Shulman and to and
upon the successors and assigns of the Corporation, respectively.

     18. Entire Agreement: This Agreement constitutes the entire agreement between the parties
hereto with respect to the terms and conditions of employment of Dr. Shulman and cancels and
supersedes any prior understandings and agreements between the parties to this Agreement. There
are no representations, warranties, forms, conditions, undertakings or collateral agreements
expressed, implied or statutory between the parties hereto other than as expressly set forth in
this Agreement.

     19. Severability: Whenever possible, each provision of this Agreement will be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law
or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any
other provision of any other jurisdiction but this Agreement will be reformed, construed and
enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been
contained herein.

-5-

 

     20. Amendments and Waivers: Any provision of this Agreement may be amended or waived only
with prior written consent of the Corporation and Dr. Shulman.

     IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first above
written.

	 	 	 	 	 	 	 	 
	ATTEST:

 	 	DUSA PHARMACEUTICALS, INC.

 	 
	/s/ Janet Kwiecien
 	 	By:  	/s/ Anthony Schincariol
 	 
	Janet Kwiecien 	 	 	Anthony Schincariol 	 
	 	 	 	Vise-President of Corporate Development 	 
	 
	WITNESS:

 	 	 

 	 
	/s/ Shari Lovell
 	 	/s/ D. Geoffrey Shulman
 	 
	Shari Lovell 	 	D. Geoffrey Shulman, MD, FRCPC 	 
	 	 	 	 
	 

-6-EX-10.II

 

Exhibit 10(ii)

EMPLOYMENT AGREEMENT

     This Agreement (“Agreement”) made as of this 4th day of April, 2006, between DUSA
Pharmaceuticals, Inc., a New Jersey corporation (“DUSA”) and William O’Dell (“O’Dell”).

     WHEREAS, O’Dell wishes to be employed by DUSA and DUSA wishes to employ O’Dell on the terms
and conditions set forth in this Agreement, and

     WHEREAS, DUSA and O’Dell wish to enter this Agreement for their mutual benefit.

     NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

     1. Employment: DUSA hereby employs O’Dell and he hereby accepts such employment as the
Executive Vice President, Sales and Marketing effective on or about April 17, 2006. O’Dell agrees
to work on a full-time basis and to devote his best efforts and spend as much time and attention as
is necessary to manage the sales and marketing functions of DUSA. O’Dell shall report to the
President of DUSA. O’Dell agrees to abide by the DUSA’s Business Code of Ethics and Senior Officers
Code of Ethics as in force from time to time.

     2. Duties and Responsibilities: Notwithstanding any language contained herein to the
contrary, O’Dell shall be responsible (by way of example and not by way of limitation) for:

     A. the supervision and oversight of all sales activities and sales compensation
programs;

     B. the supervision and oversight of all marketing initiatives for DUSA’s products;

     C. identify opportunities for market penetration, revenue growth and profitability of
DUSA’s products;

     D. identification of corporate partnering opportunities to co-develop and market DUSA’s
products; and

     E. any additional employment responsibilities as deemed appropriate by the Board of
Directors and DUSA’s senior management, from time to time.

     3. Remuneration: DUSA will pay to O’Dell a base salary equal to Two Hundred Fifty Thousand
Dollars ($250,000.00) per annum at intervals consistent with DUSA’s administrative practices, from
time to time. This base salary shall be reviewed by the Board of Directors of DUSA from time to
time, not less than on an annual basis, beginning in January, 2007. Any salary increases shall be
determined by, and shall be made at the sole discretion of the Board. Following the end of each
fiscal year, the Board may award a cash bonus to O’Dell in an amount up to 35% of his current base
salary for such year, as determined by the Board in its sole discretion. For purposes of awarding
the total amount of such bonus, mutually agreeable performance objectives will be set at the
beginning of any calendar year during O’Dell’s employment. The Board may award annual cash bonuses
above 35% of then current base salary for outstanding performance.

 

 

     All salary and other payments and allowances outlined in this Agreement shall be subject to
such withholding taxes and deductions as may be required by law.

     4. Place of Employment: As Executive Vice President of Sales and Marketing, O’Dell will
operate primarily from the offices of DUSA located in Wilmington, MA. O’Dell acknowledges,
however, that there will be domestic and international travel required on a regular basis. Such
travel is understood to be necessary in order to promote the business of DUSA.

     5. Benefits: O’Dell will be entitled to participate in the medical, disability, life, and
other insurance benefit plans or pension, profit sharing, deferred compensation, equity incentive
plans, or 401K plans which may be made available to the officers and employees of DUSA from time to
time, subject to applicable eligibility rules thereof.

     6. Stock Options: O’Dell shall be entitled to participate in the 1996 Omnibus Plan, as
amended, and any subsequent stock purchase and bonus or incentive plans that DUSA shall from time
to time make available to its officers and employees, subject to applicable eligibility rules
thereof. Management of DUSA agrees to recommend to the Compensation Committee that O’Dell be
granted options for Fifty Thousand (50,000) shares of DUSA’s common stock pursuant to the vesting
and other provisions of the Plan.

     7. Vacation: O’Dell shall be entitled to four (4) weeks of vacation during each year of
employment, to be taken at a time or times acceptable to DUSA, having regard to its operations.
O’Dell shall not be entitled to carry over any unused vacation from one (1) calendar year into the
following calendar year, so long as such a vacation policy is consistent for all employees.

     8. Expenses: All reasonable travel and other expenses incident to the rendering of services
by O’Dell on behalf of and in promoting the interests of DUSA shall be paid by DUSA, including but
not limited to an automobile allowance in the amount of $8,400 per year plus insurance. If such
expenses are paid in the first instance by O’Dell, DUSA agrees that it will reimburse him therefore
upon presentation of appropriate statements, vouchers, bills and invoices as and when required by
DUSA to support the reimbursement request. In addition, DUSA will provide the following relocation
assistance:

     All closing costs for the sale and purchase of housing as listed on the respective HUD-1,
RESPA statements;

Reasonable packing and moving costs of household items;

Interim reasonable living expenses for up to six (6) months;

     9. Confidential Information:

     A. O’Dell understands that in the performance of his services hereunder he may obtain
knowledge of “confidential information”, as hereinafter defined, relating to the business of
DUSA. As used herein, “confidential information” means any information (whether clinical,
financial, administrative or otherwise), written or oral, (including without limitation, any
formula, pattern, device, plan, process, or compilation of information) which (i) is, or is
designed to be, used in the business of DUSA or results from its research and/or development
activities, or (ii) is private or confidential in that it is not generally known or
available to the public, or (iii) gives DUSA an opportunity to obtain an advantage over
competitors who do not know or use it. O’Dell shall not, without the written consent of the
Board, either during the term of his employment or thereafter, (a) use or disclose any such
confidential information outside of DUSA (except to consultants or other agents or
representatives of DUSA who are similarly bound to DUSA by confidentiality obligations), (b)
publish any article with respect thereto, (c) except in the performance of his services
hereunder, remove or aid in the removal from

-2-

 

the premises of DUSA any such confidential information or any property or material
which relates thereto.

     B. Upon the termination of his employment with DUSA, all documents, records, notebooks
and similar repositories of or continuing information concerning DUSA, or its products,
services or customers, including any copies thereof, then in O’Dell’s possession or under
his control, whether prepared by O’Dell or others, will be left with or immediately returned
to DUSA by O’Dell.

     C. (i) O’Dell shall promptly disclose to DUSA any and all prescription drug products,
devices, machines, methods, inventions, discoveries, improvements, processes, works or the
like (all of which are referred to herein as “inventions”) which he may invent, conceive,
produce, or reduce to practice, either solely or jointly with others, at any time (whether
or not during work hours) during his employment hereunder.

          (ii) All such inventions which in any way relate to the products manufactured, sold or
used by DUSA or to any methods, processes or apparatus used in connection with the
manufacture of such products or treatment of disease or conditions, or in either case which
are or may be or may become capable of use in the business of DUSA, shall at all times and
for all purposes be regarded as acquired and held by O’Dell in a fiduciary capacity for,
solely for the benefit of, DUSA.

          (iii) With respect to all such inventions, O’Dell shall:

     (a) treat all information with respect thereto as confidential
information within the meaning of, and subject to this paragraph 9;

     (b) keep complete and accurate records thereof, which records shall be
the property of DUSA;

     (c) execute any application for letters patent of the United States and
of any and all other countries covering such inventions, and give to DUSA,
its attorneys and solicitors all reasonable and requested assistance in
preparing such application;

     (d) from time to time, upon the request and at the expense of DUSA, but
without charge for services beyond the salary paid to him by DUSA, execute
all assignment or other instruments required to transfer and assign to DUSA
(or as it may direct) all inventions, and all patents and applications for
patents, copyrights or applications for registration of copyrights, covering
such inventions or otherwise required to protect the rights and interests of
DUSA;

     (e) testify in any proceedings or litigation as to all such inventions;
and

     (f) in case DUSA shall desire to keep secret any such invention, or
shall for any reason decide not to have letters patent applied for thereon,
refrain from applying for letters patent thereon.

     D. Notwithstanding any of the foregoing in this section, information, whether
confidential or proprietary or not, shall be exempt from the above confidentiality
provisions if said information:

-3-

 

	 	(i)	 	is known to O’Dell prior to his employment or
consultancy with DUSA;
	 
	 	(ii)	 	is in the public domain on the date of
employment;
	 
	 	(iii)	 	becomes public at any time through no fault of
O’Dell; or
	 
	 	(iv)	 	is or becomes readily available from third
parties who have no confidentiality obligations to DUSA.

     E. If O’Dell’s employment is terminated by O’Dell, O’Dell shall not, without the
express prior written consent of DUSA, directly, or indirectly, during the term of this
Agreement or for a period of one (1) year after its termination, render services, or engage
in activity including but not limited to, the activities enumerated in Section 2 hereof or
any similar activity, for any company which relates to the development or sale of
photodynamic therapy (“PDT”) or photodetection (“PD”) products, or other products directly
competitive (i.e., medically or therapeutically) with DUSA’s products or compounds or
mixtures thereof, or potential products in development by DUSA, whether alone or as a
partner, officer, director, employee or shareholder of any other corporation, or as a
trustee, fiduciary, consultant or other representative of any other activity. This
restriction shall not apply if O’Dell has disclosed to DUSA, in writing, all the known facts
relating to such work or activity and has received a release, in writing from DUSA, to
engage in such work or activity. The making of passive and personal investments and the
conduct of private business affairs shall not be prohibited hereunder. Ownership by O’Dell
of five percent (5%) or less of the outstanding shares of stock of any corporation either
(i) listed on a national securities exchange or (ii) having at least 100 stockholders shall
not make O’Dell a “stockholder” within the meaning of that term as used in this paragraph,
so long as O’Dell has no participation in the management of such corporation.

     10. Termination of Employment:

     A. DUSA may terminate this Agreement at any time, with or without cause on sixty (60)
days prior written notice. For purposes of this Agreement, cause shall mean (i) O’Dell’s
physical or mental disability or other inability to perform the duties of his job for any
reason for a period in excess of six (6) consecutive months, (ii) O’Dell’s conviction in a
court of law of a crime or offense, which conviction would prevent O’Dell from effective
management of DUSA or materially adversely affect the reputation of DUSA, as determined by
the Board in its sole discretion, exercising its reasonable judgment, or (iii) O’Dell’s
malfeasance or misconduct such as fraud, embezzlement, dishonesty, acts of moral turpitude,
or a felony conviction, or for other good cause materially detrimental to DUSA. In the
event of a termination for cause, O’Dell shall be paid his base salary, pro rated to the
date of termination. Nothing contained herein shall be interpreted to impair or otherwise
affect the right of DUSA to terminate O’Dell’s employment, at will, with or without good
cause.

     B. If O’Dell’s employment is terminated by DUSA without cause, DUSA shall:

     (i) pay O’Dell a severance allowance equivalent to twelve (12) month’s then
current base salary, payable as a lump sum, within sixty (60) days following the
date of such termination;

     (ii) pay to O’Dell within two (2) weeks of the date of termination all
outstanding vacation pay and any earned but unpaid salary or bonuses to the date of
such termination and reimburse O’Dell for any business expense incurred by

-4-

 

him up to and including the date of such termination following provision by
O’Dell of all applicable and necessary receipts.

     C. Termination upon Death: O’Dell’s employment with DUSA will cease and this Agreement
will terminate without further compensation if O’Dell dies. Upon his death, his estate will
be entitled to any Corporation paid death benefit in force at the time of such death. In
addition, O’Dell’s estate shall be paid any cash bonus to which he would have been entitled
under Paragraph 3 above. Likewise, O’Dell’s beneficiaries as designated by him to DUSA shall
be entitled to receive the benefits, if any, described in Paragraphs 5 and 6 above, and will
be entitled to exercise any vested but unexercised stock options that were held by him at
the time of his death, subject to the terms and conditions of such options.

     D. Resignation: O’Dell will provide DUSA with two (2) months’ advance notice, in
writing, of his resignation from DUSA.

     11. Change of Control: If O’Dell’s employment is terminated by DUSA without cause upon the
consummation of a “change in control” as defined herein, O’Dell shall receive, within five (5) days
after such termination from DUSA or its successor, a lump sum payment equal to three (3) times his
base salary during the last fiscal year in which O’Dell is associated with DUSA (including any
amounts due as severance under Paragraph 10B.(i) of this Agreement). For the purposes hereof,
“change in control” shall mean a change in control of a nature that would be required to be
reported in response to Item 5 of Schedule 14D promulgated pursuant to section 14 of the Securities
Exchange Act of 1934, as amended (the 1934 Act”), whether or not DUSA is then subject to such
reporting requirements; provided that, without limitations, such a change in control shall be
deemed to have occurred if (i) any person other than a trustee or other fiduciary holding
securities under an employee benefit plan of DUSA is or becomes the beneficial owner, directly or
indirectly, of securities of DUSA representing twenty percent (20%) or more of the combined voting
power of DUSA’s then outstanding securities and thereafter the Board adopts a resolution to the
effect that, for the purposes of this Agreement, a change in control of DUSA has occurred; such
ownership shall be defined pursuant to Rule 13d-3 of the 1934 Act and includes mergers or
acquisitions whereby an outside party has in excess of twenty percent (20%) of the combined voting
power; (ii) when DUSA merges or consolidates with any other person or, entity other than a
subsidiary and, upon consummation of such transaction own less than fifty percent (50%) of the
equity securities of the surviving or consolidated entity; or (iii) a substantial portion of the
assets of DUSA are sold or transferred to another person or entity.

     12. Indemnification: DUSA will, to the extent permitted by the laws of the State of New
Jersey, indemnify O’Dell against any actual or threatened action, suit or proceeding, whether
civil, criminal, administrative or investigative, that arises as a consequence of his duties as an
employer and officer of DUSA. Such indemnification will include such expenses as attorneys fees,
judgments, fines and amounts awarded or agreed to in settlement, provided that O’Dell acted legally
and in good faith, or reasonably believed that his actions were legal and performed in good faith.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or
upon a plea of nolo contendre shall not, of itself, create a presumption that his actions were
illegal or not performed in good faith.

     13. Representation Concerning Prior Employment: O’Dell represents and warrants to DUSA that
none of the duties or obligations for which he is responsible under this Employment Agreement
breaches, or will cause him to breach in the future, any restrictive covenant or confidentiality
obligation under any former employment agreement.

-5-

 

     14. Provisions Operating Following Termination: Notwithstanding any termination of O’Dell’s
employment with or without cause, any provision of this Agreement necessary to give it efficacy
shall continue in full force and effect following such termination.

     15. Notices: Any notice to be given in connection with this Agreement shall be given in
writing and may be given by personal delivery, by certified mail, postage prepaid, or by facsimile
transmission, so long as receipt of such transmission is available, addressed to the recipient as
follows:

	 	 	 	 	 
	 

	 	To:
	 	William O’Dell

74 Durham Road

Skillman, NJ 08558
	 
	 	 	 	 
	 

	 	To:
	 	Robert F. Doman, President

DUSA Pharmaceuticals, Inc.

25 Upton Drive

Wilmington, Massachusetts 01887

or to such other address or individual as may be designated by notice by either party to the other.
Any notice given by personal delivery shall be deemed to have been given on the day of actual
delivery and, if made or given by certified mail, on the third day, other than a Saturday or Sunday
following the deposit thereof with the U.S. Postal Service.

     16. Governing Law: This Agreement shall be governed by and construed in accordance with the
laws of the State of New Jersey.

     17. Benefit of Agreement: This Agreement shall enure to the benefit of and be binding upon
the heirs, executives, administrators and legal personal representatives of O’Dell and to and upon
the successors and assigns of DUSA, respectively.

     18. Entire Agreement: This Agreement constitutes the entire agreement between the parties
hereto with respect to the terms and conditions of employment of O’Dell and cancels and supersedes
any prior understandings and agreements between the parties to this Agreement. There are no
representations, warranties, forms, conditions, undertakings or collateral agreements expressed,
implied or statutory between the parties hereto other than as expressly set forth in this
Agreement.

     19. Severability: Whenever possible, each provision of this Agreement will be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law
or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any
other provision of any other jurisdiction but this Agreement will be reformed, construed and
enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been
contained herein.

     20. Amendments and Waivers: Any provision of this Agreement may be amended or waived only
with prior written consent of DUSA and O’Dell.

-6-

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement.

	 	 	 	 	 
	ATTEST:	 	DUSA PHARMACEUTICALS, INC.
	 
	 	 	 	 
	 
	 	 	 	 
	/s/
Susan B. Tennent

	 	By:
	 	/s/ Robert F. Doman
	 

	 	 	 
	 

	 	 	 	Robert F. Doman, President & COO
	 
	 	 	 	 
	 

	 	Dated:
	4-4-06
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	WITNESS:	 	EMPLOYEE:
	 
	 	 	 	 
	 
	 	 	 	 
	/s/
Susan M. Campbell

	 	By:
	 	/s/ William O’Dell
	 

	 	 	 
	 

	 	 	 	William O’Dell
	 
	 	 	 	 
	 

	 	Dated:
	4-4-06
	 

	 	 	 	 

-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]